Research study Program year 2025 Source: CMS Open Payments

M20-259 - Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD)

Research payments

$38,684

24 payments

Through program year 2025, $38,684 in research payments was reported against M20-259 - Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD), across 24 payments, paid by AbbVie, Inc..

Paid by: AbbVie, Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

1 row

Year	Kind	Amount	Payments
2025	Research	$38,684	24

Breakdown

Who paid Research payments · program year 2025

AbbVie, Inc. $38,684 24 payments

Who received the money Research payments · program year 2025

Tyler Research Institute LLC Organisation paid for research $8,967 2 payments
Mayo Clinic Organisation paid for research $8,100 1 payment
Texas Digestive Disease Consultants Pllc Organisation paid for research $4,371 3 payments
University Of Louisville Organisation paid for research $4,159 2 payments
Uc Healthcare System Organisation paid for research $2,447 2 payments
Richmond Va Medical Center (151) Organisation paid for research $2,307 3 payments
Gastroenterology Associates Of Central Georgia LLC Organisation paid for research $2,272 3 payments
Feinstein Institute for Medical Research Organisation paid for research $2,178 3 payments
Hightower Clinical Llc Organisation paid for research $2,000 1 payment
Nature Coast Clinical Research LLC Organisation paid for research $1,679 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.